These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34018462)

  • 1. Effects of pirfenidone on renal function in patients with interstitial pneumonia.
    Matsumoto J; Sunohara K; Mori Y; Nagaya H; Inaba S
    Ren Fail; 2021 Dec; 43(1):879-881. PubMed ID: 34018462
    [No Abstract]   [Full Text] [Related]  

  • 2. [The clinical experience of pirfenidone based on corticosteroids and immunosuppressant treatment for interstitial pneumonia with autoimmune features].
    Huang H; Sun YX; Li S; Shao C; Xu K; Xu ZJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Sep; 42(9):700-704. PubMed ID: 31484245
    [No Abstract]   [Full Text] [Related]  

  • 3. Pirfenidone induced phototoxic reaction in an elderly man.
    Gaikwad RP; Mukherjee SS
    Indian J Dermatol Venereol Leprol; 2016; 82(1):101-3. PubMed ID: 26728829
    [No Abstract]   [Full Text] [Related]  

  • 4. A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: A CARE-compliant article.
    Huang H; Feng RE; Li S; Xu K; Bi YL; Xu ZJ
    Medicine (Baltimore); 2016 Jul; 95(27):e4113. PubMed ID: 27399114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis.
    Li T; Guo L; Chen Z; Gu L; Sun F; Tan X; Chen S; Wang X; Ye S
    Sci Rep; 2016 Sep; 6():33226. PubMed ID: 27615411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of pirfenidone in pediatric patients with interstitial lung disease and pulmonary fibrosis.
    McKinzie CJ; Gower WA; Hagood JS; Vece TJ
    Pediatr Pulmonol; 2023 Aug; 58(8):2396-2398. PubMed ID: 37161910
    [No Abstract]   [Full Text] [Related]  

  • 7. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.
    Nagai S; Hamada K; Shigematsu M; Taniyama M; Yamauchi S; Izumi T
    Intern Med; 2002 Dec; 41(12):1118-23. PubMed ID: 12521199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
    Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
    Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
    Khanna D; Albera C; Fischer A; Khalidi N; Raghu G; Chung L; Chen D; Schiopu E; Tagliaferri M; Seibold JR; Gorina E
    J Rheumatol; 2016 Sep; 43(9):1672-9. PubMed ID: 27370878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease.
    Katano T; Sekine A; Ikeda S; Yamakawa H; Misumi T; Okabayashi H; Okuda R; Kitamura H; Baba T; Komatsu S; Hagiwara E; Ogura T
    Respir Investig; 2021 Jul; 59(4):414-420. PubMed ID: 33618993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE.
    Deng L; Chen Y; Hu X; Zhou J; Zhang Y
    Front Immunol; 2021; 12():708463. PubMed ID: 34671344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.
    Uehara M; Enomoto N; Oyama Y; Suzuki Y; Kono M; Furuhashi K; Fujisawa T; Inui N; Nakamura Y; Suda T
    Respirology; 2018 Mar; 23(3):318-324. PubMed ID: 28851013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Approach to Adult Fibrotic Lung Diseases.
    Adegunsoye A; Strek ME
    Chest; 2016 Dec; 150(6):1371-1386. PubMed ID: 27521738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
    Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease.
    Miura Y; Saito T; Fujita K; Tsunoda Y; Tanaka T; Takoi H; Yatagai Y; Rin S; Sekine A; Hayashihara K; Nei T; Azuma A
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):235-8. PubMed ID: 25363224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone combined with corticosteroids in a patient with systemic lupus erythematosus-associated interstitial lung disease.
    Yang BB; Man XY; Zheng M
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e388-e389. PubMed ID: 28261880
    [No Abstract]   [Full Text] [Related]  

  • 18. Update in Interstitial Lung Disease 2014.
    Belloli EA; Martinez FJ; Flaherty KR
    Am J Respir Crit Care Med; 2015 Sep; 192(5):538-43. PubMed ID: 26561676
    [No Abstract]   [Full Text] [Related]  

  • 19. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update in diffuse parenchymal lung disease 2011.
    Luckhardt TR; Müller-Quernheim J; Thannickal VJ
    Am J Respir Crit Care Med; 2012 Jul; 186(1):24-9. PubMed ID: 22753686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.